Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 28

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 28
---
 share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track continued to insist on the appointment of Brett Erkman and failed to offer an appropriate standstill …But Deep Track Would Not Negotiate in Good Faith (3/3) © Copyright DYNAVAX 2025 38 | DVAX 5 th Proposal (1/30) – Same as 4 th Proposal • Appointment of 2 independent Deep Track nominees • Retirement of 2 incumbent directors • 1 - year standstill agreement 5 (+) improvement in offered terms vs. prior offer ( - ) worsening of offered terms vs. prior offer Deep Track Counterproposal (4/10) • Appointment of 2 Deep Track nominees (including Brett Erkman ) ( - ) • Retirement of 2 incumbent directors (+) • No standstill agreement ( - ) • Reclassify the Board and split directors into three classes (+) • No request for Chair to step down (+) • No share repurchase stipulation (+) 5 Deep Track continued to insist on the appointment of Brett Erkman and reinstated their demand for an increased share buyback DVAX 6 th Proposal (4/25) – Same as 4 th Proposal • Appointment of 2 independent Deep Track nominees • Retirement of 2 incumbent directors • 1 - year standstill agreement 6 Deep Track Counterproposal (4/17) • Appointment of 2 Deep Track nominees (including Brett Erkman ) • Retirement of 2 incumbent directors • 2 - year standstill agreement (+) • Donald to be added to Nominating and Corporate Governance Committee ( - ) • Brett to be added to the Compensation Committee and renominated by the company at the 2026 AGM ( - ) • Increase share repurchase program another $200M ($100M in immediate ASR) ( - ) 6

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track’s Campaign Would Remove Proven Strategic Leadership at a Critical Moment 39 | Scott Myers Independent Chairman of the Board since October 2021 x Considerable experience as a pharmaceutical executive: With over three decades of expertise in the global pharmaceutical and medical technology industries x Successful public company CEO background: Served as CEO of